MARLBOROUGH, Mass., Aug. 15, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) today announced completion of an agreement between its Cynosure division and Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument's nitrous oxide and oxygen system, Nitronox™. Cynosure is the first medical aesthetic manufacturer to offer a nitrous oxide and oxygen system to its customers.
Nitronox is a self-administered nitrous oxide and oxygen delivery system providing a fast-acting inhaled analgesic that helps patients manage potential discomfort and anxiety while remaining alert and conscious during their aesthetic procedures. Nitrous oxide and oxygen have been used safely and effectively for more than 100 years for pain management. More recently, Nitronox devices' non-invasive delivery system has developed a strong track record in labor and delivery as well as in outpatient medical settings.
"We are very excited to partner Porter Instrument's longstanding leadership and innovation in the nitrous oxide category with our market-leading medical aesthetics offerings," said Kevin Thornal, Hologic's Division President, Cynosure. "This agreement allows us to provide our existing and future customers a distinct competitive advantage: an unparalleled, more comfortable patient experience."
Commenting on the agreement, Jay Reidy, General Manager of Parker's Precision Fluidics Division - Porter Instrument business, said, "We are excited to partner with Cynosure, a leader within the medical aesthetic market. Our gas delivery products provide an ideal solution for pain management and patient anxiety during various procedures. Combined with the strength of Cynosure's commercial and service teams, this will be a winning combination for both physicians and patients."
Hologic anticipates that Nitronox will be used to complement hair removal, tattoo removal, body contouring and skin revitalization procedures.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic and Cynosure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
SOURCE Hologic, Inc.